About Our Team

We believe in unlocking the power of MRD to transform cancer care for patients and clinicians alike. At NoRD Bio, we are committed to advancing the field of MRD monitoring and bringing this cutting-edge technology to the forefront of cancer treatment.

Our mission is to make MRD monitoring accessible and affordable for patients and clinicians around the world. We are developing innovative, user-friendly tools and technologies that enable accurate and reliable MRD testing, with fast turnaround times and actionable results.

At NoRD Bio, we believe that MRD monitoring has the potential to revolutionize cancer care, enabling earlier detection of relapse, more personalized and effective treatments, and better outcomes for patients. Join us in unlocking the power of MRD for the benefit of all cancer patients!

Meet the Team

Ida Pavlichenko, PhD
Ida, CEO of NoRD Bio, is a serial entrepreneur, innovator, and R&D leader with experience across startups, academia, and government. Previously, she co-founded and led a medtech company pioneering biomaterials for medical implants. Recognized with awards like MIT TR Innovators Under 35 and MassNextGen, her focus is on translating advanced science into practical medical solutions that enhance patient care.
Ignaty Leshchiner, PhD
Associate Professor in Computational Biomedicine at the Boston University School of Medicine. Ignaty is a leading academic in the field of cancer computational biology. Focused on applying new genomic technologies, computational analysis and AI methods unravelling biology behind tumor development, treatment evasion, and progression to metastasis.
Dimitri Livitz, PhD
As Director of Data Science, Dimitri applies statistical and AI models to real-world cancer data to advance cancer therapies. Previously at the Broad Institute of Harvard and MIT, he studied cancer heterogeneity and treatment resistance, co-authoring high-profile publications in Nature, Nature Medicine, and Cell. He holds a PhD from Columbia University for his research in Bayesian experimental design, which has laid the foundation for his current work.
Paul Trukhanov
Experienced startup entrepreneur with expertise in biotechnology, healthcare, data-intensive software engineering, which resulted in two successful startup exits. Paul have previously build web-scale software systems and now Paul leads data analysis software development teams as a Software Architect in Machine Learning at Dana Farber Cancer Institute.
Elizaveta Leshchiner, PhD
Dr. Liza Leshchiner is focused on experimental and computational biology of cancer. She has strong expertise in technology and high-throughput assay development, including genomic and screening assays. She earned her Ph.D. from Harvard University and is leading a team of scientists at the Broad Institute of Harvard and MIT.
Andrew Jacobs, JD
Andy has a 40-year record of starting, managing and growing multitude of small and medium sized companies. He currently serves as president and a Board Member for companies in the area of computational services and data management for cancer patients and has been heavily involved in several non-profit enterprises.
Roger Jacobs, MBA
Roger is an executive with over 40 years of management and business development experience. For the past 20 years he has been on the Board and/or acted in a CEO/CFO/COO capacity in a number of companies in SaaS, bioinformatics and biological services. In his spare time Roger enjoys renovating an historic mansion on Chautauqua Lake, NY

Who do we serve?

Our client portfolio consists of cancer therapeutics developers all over the U.S.

Focusing on advanced NGS assays for cancer research projects and specifically MRD monitoring is at the core of our expertise.

Accumulation of expertise and insight that is available to our future clients as well as our innovative approaches due to a diverse background and experiences – is what sets us aside.

Check out our case studies